دورية أكاديمية
أعرض في EDS

Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study.

التفاصيل البيبلوغرافية
العنوان: Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study.
المؤلفون: D'Ambrosio R; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, CRC A.M. e A. Migliavacca Center for Liver Diseases, Gastroenterology and Hepatology, Milan, Italy. Electronic address: roberta.dambrosio@policlinico.mi.it., Pasulo L; ASST Papa Giovanni XXIII, Bergamo HCV Network, Bergamo, Italy., Giorgini A; ASST Santi Paolo e Carlo, Gastroenterology and Hepatology, Milan, Italy., Spinetti A; ASST Brescia, Brescia HCV Network, Brescia, Italy., Messina E; San Raffaele Hospital, Infectious Diseases, Milan, Italy., Fanetti I; San Giuseppe Hospital, Università degli Studi di Milano, Hepatology, Milan, Italy., Puoti M; ASST Grande Ospedale Metropolitano Niguarda, Infectious Diseases, Milan, Italy., Aghemo A; Humanitas Research Hospital, Humanitas University, Internal Medicine and Hepatology, Milan, Italy., Viganò P; ASST Ovest Milanese, Infectious Diseases, Milan, Italy., Vinci M; ASST Grande Ospedale Metropolitano Niguarda, Gastroenterology and Hepatology, Milan, Italy., Menzaghi B; Busto Arsizio Hospital, ASST Valle Olona, Infectious Diseases, Busto Arsizio, Italy., Lombardi A; Fondazione IRCCS Policlinico San Matteo, University of Pavia, Infectious Diseases, Pavia, Italy., Pan A; ASST Cremona, Infectious Diseases, Cremona, Italy., Pigozzi MG; ASST Brescia, Brescia HCV Network, Brescia, Italy., Grossi P; Ospedale di Circolo e Fondazione Macchi, Infectious Diseases, Varese, Italy., Lazzaroni S; ASST Papa Giovanni XXIII, Bergamo HCV Network, Bergamo, Italy., Spinelli O; ASST Lariana, Como, Italy., Invernizzi P; San Gerardo Hospital, Gastroenterology and Hepatology, Monza, Italy., Maggiolo F; ASST Papa Giovanni XXIII, Bergamo HCV Network, Bergamo, Italy., Terreni N; Valduce Hospital, Gastroenterology, Como, Italy., Monforte AD; ASST Santi Paolo e Carlo, Gastroenterology and Hepatology, Milan, Italy., Poggio PD; ASST Papa Giovanni XXIII, Bergamo HCV Network, Bergamo, Italy., Taddei MT; ASST Santi Paolo e Carlo, Gastroenterology and Hepatology, Milan, Italy., Colombo S; ASST Papa Giovanni XXIII, Bergamo HCV Network, Bergamo, Italy., Pozzoni P; ASST Lecco, Internal Medicine, Lecco, Italy., Molteni C; ASST Lecco, Infectious Diseases, Lecco, Italy., Brocchieri A; ASST Lodi, Internal Medicine, Lodi, Italy., Bhoori S; Fondazione IRCCS Istituto Nazionale Tumori di Milano, General Surgery and Liver Transplantation Unit, Milan, Italy., Buscarini E; Maggiore Hospital, ASST Crema, Gastroenterology, Crema, Italy., Centenaro R; ASST Melegnano Martesana, Internal Medicine, Milan, Italy., Mendeni M; ASST Brescia, Brescia HCV Network, Brescia, Italy., Colombo AE; ASST Lariana, Como, Italy., Di Marco M; ASST Papa Giovanni XXIII, Bergamo HCV Network, Bergamo, Italy., Dionigi E; ASST Melegnano Martesana, Internal Medicine, Milan, Italy., Bella D; ASST Brescia, Brescia HCV Network, Brescia, Italy., Borghi M; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, CRC A.M. e A. Migliavacca Center for Liver Diseases, Gastroenterology and Hepatology, Milan, Italy., Zuin M; ASST Santi Paolo e Carlo, Gastroenterology and Hepatology, Milan, Italy., Zaltron S; ASST Brescia, Brescia HCV Network, Brescia, Italy., Noventa F; QUOVADIS No Profit Association, Univerisity of Padua, Padua, Italy., Annalisa S; Fondazione IRCCS Policlinico San Matteo, Clinical Epidemiology and Biometric Unit, Pavia, Italy., Lampertico P; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, CRC A.M. e A. Migliavacca Center for Liver Diseases, Gastroenterology and Hepatology, Milan, Italy., Fagiuoli S; ASST Papa Giovanni XXIII, Bergamo HCV Network, Bergamo, Italy.
المصدر: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver [Dig Liver Dis] 2020 Feb; Vol. 52 (2), pp. 190-198. Date of Electronic Publication: 2019 Dec 06.
نوع المنشور: Journal Article; Multicenter Study
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 100958385 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-3562 (Electronic) Linking ISSN: 15908658 NLM ISO Abbreviation: Dig Liver Dis Subsets: MEDLINE
أسماء مطبوعة: Publication: 2003- : Amsterdam : Elsevier
Original Publication: Roma, Italy : Editrice gastroenterologica italiana, c2000-
مواضيع طبية MeSH: Antiviral Agents/*therapeutic use , Hepatitis C, Chronic/*drug therapy , Sofosbuvir/*therapeutic use, Adult ; Aged ; Aged, 80 and over ; Antiviral Agents/adverse effects ; Drug Therapy, Combination ; Female ; Genotype ; Glomerular Filtration Rate ; Hepacivirus ; Hepatitis C, Chronic/pathology ; Humans ; Italy ; Logistic Models ; Male ; Middle Aged ; Renal Insufficiency, Chronic/complications ; Renal Insufficiency, Chronic/physiopathology ; Retrospective Studies ; Sofosbuvir/adverse effects ; Sustained Virologic Response ; Young Adult
مستخلص: Background: Sofosbuvir (SOF)-based regimens have been associated with renal function worsening in HCV patients with estimated glomerular filtration rate (eGFR) ≤ 45 ml/min, but further investigations are lacking.
Aim: To assess renal safety in a large cohort of DAA-treated HCV patients with any chronic kidney disease (CKD).
Methods: All HCV patients treated with DAA in Lombardy (December 2014-November 2017) with available kidney function tests during and off-treatment were included.
Results: Among 3264 patients [65% males, 67% cirrhotics, eGFR 88 (9-264) ml/min], CKD stage was 3 in 9.5% and 4/5 in 0.7%. 79% and 73% patients received SOF and RBV, respectively. During DAA, eGFR declined in CKD-1 (p < 0.0001) and CKD-2 (p = 0.0002) patients, with corresponding rates of CKD stage reduction of 25% and 8%. Conversely, eGFR improved in lower CKD stages (p < 0.0001 in CKD-3a, p = 0.0007 in CKD-3b, p = 0.024 in CKD-4/5), with 33-45% rates of CKD improvement. Changes in eGFR and CKD distribution persisted at SVR. Baseline independent predictors of CKD worsening at EOT and SVR were age (p < 0.0001), higher baseline CKD stages (p < 0.0001) and AH (p = 0.010 and p < 0.0001, respectively).
Conclusions: During DAA, eGFR significantly declined in patients with preserved renal function and improved in those with lower CKD stages, without reverting upon drug discontinuation.
(Copyright © 2019 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.)
فهرسة مساهمة: Keywords: CKD; Kidney; SVR; eGFR
المشرفين على المادة: 0 (Antiviral Agents)
WJ6CA3ZU8B (Sofosbuvir)
تواريخ الأحداث: Date Created: 20191210 Date Completed: 20201215 Latest Revision: 20201215
رمز التحديث: 20231215
DOI: 10.1016/j.dld.2019.11.006
PMID: 31813755
قاعدة البيانات: MEDLINE
الوصف
تدمد:1878-3562
DOI:10.1016/j.dld.2019.11.006